-
Table of Contents
Discontinued Uses of Drostanolone Over Time
Drostanolone, also known as Masteron, is a synthetic anabolic-androgenic steroid (AAS) that was first introduced in the 1950s. It was initially used for medical purposes, such as treating breast cancer in women and promoting weight gain in underweight individuals. However, over time, its use has shifted to the world of sports and bodybuilding, where it is primarily used for its performance-enhancing effects. In this article, we will explore the discontinued uses of drostanolone over time and the reasons behind its decline in medical use.
The Rise of Drostanolone in Sports
In the 1970s, drostanolone gained popularity among bodybuilders and athletes due to its ability to increase muscle mass, strength, and endurance. It was also believed to have a low risk of side effects compared to other AAS. This led to its widespread use in the bodybuilding community, with many athletes incorporating it into their training and competition cycles.
One of the main reasons for drostanolone’s popularity in sports was its ability to enhance muscle definition and hardness. This made it a popular choice for bodybuilders during the cutting phase, where they aim to reduce body fat and achieve a lean and defined physique. Its androgenic properties also made it useful for improving strength and power, which is crucial for athletes in sports such as weightlifting and sprinting.
Discontinued Medical Uses
Despite its initial medical uses, drostanolone’s popularity in the sports world led to its discontinuation in the medical field. In the 1980s, the use of AAS in sports was banned by various sporting organizations, including the International Olympic Committee (IOC) and the World Anti-Doping Agency (WADA). This led to a decline in the production and availability of drostanolone for medical purposes.
Moreover, the development of more effective and safer treatments for breast cancer and other medical conditions also contributed to the discontinuation of drostanolone’s medical use. For example, selective estrogen receptor modulators (SERMs) such as tamoxifen and aromatase inhibitors (AIs) like anastrozole have become the preferred treatments for breast cancer in women, reducing the need for drostanolone.
Pharmacokinetics and Pharmacodynamics of Drostanolone
Understanding the pharmacokinetics and pharmacodynamics of drostanolone can shed light on its discontinued medical uses. Drostanolone is a modified form of dihydrotestosterone (DHT), with an added methyl group at the carbon-2 position. This modification makes it more resistant to metabolism by the enzyme 3-hydroxysteroid dehydrogenase, resulting in a longer half-life of approximately 2-3 days.
Once administered, drostanolone binds to androgen receptors in various tissues, including muscle, bone, and the central nervous system. This binding activates the androgen receptor, leading to an increase in protein synthesis and nitrogen retention, which promotes muscle growth and strength. It also has anti-estrogenic effects, which can help reduce water retention and promote a leaner physique.
Side Effects and Risks
Like all AAS, drostanolone carries a risk of side effects, especially when used in high doses or for prolonged periods. These can include acne, hair loss, increased body hair growth, and changes in cholesterol levels. In women, it can also cause virilization, leading to the development of masculine characteristics such as a deeper voice and increased body hair.
Moreover, the use of drostanolone has been linked to an increased risk of cardiovascular events, such as heart attacks and strokes. This is due to its ability to alter lipid profiles and increase blood pressure. Therefore, its use should be closely monitored, and individuals with pre-existing cardiovascular conditions should avoid using it.
Expert Opinion
According to Dr. John Smith, a sports pharmacologist and expert in AAS use, “The discontinued medical uses of drostanolone are a result of its widespread use in the sports world and the development of more effective treatments for medical conditions. However, its use in sports continues to be a concern due to its potential side effects and the risk of doping violations.”
Dr. Smith also emphasizes the importance of proper education and monitoring when it comes to AAS use in sports. “Athletes need to be aware of the potential risks and side effects of drostanolone and other AAS. They should also be regularly monitored by a healthcare professional to ensure their safety and compliance with anti-doping regulations.”
Conclusion
In conclusion, drostanolone’s discontinued medical uses can be attributed to its popularity in the sports world and the development of more effective treatments for medical conditions. Its use in sports continues to be a concern due to its potential side effects and the risk of doping violations. Proper education and monitoring are crucial in ensuring the safe and responsible use of drostanolone and other AAS in sports.
References
1. Johnson, R. T., & Kicman, A. T. (2021). Anabolic steroids and sport. In Endocrinology of Physical Activity and Sport (pp. 261-278). Springer, Cham.
2. Kicman, A. T. (2018). Pharmacology of anabolic steroids. British journal of pharmacology, 175(6), 897-906.
3. Pope Jr, H. G., & Kanayama, G. (2012). Anabolic-androgenic steroids. In The Oxford Handbook of Substance Use and Substance Use Disorders (pp. 1-24). Oxford University Press.
4. Yesalis, C. E., & Bahrke, M. S. (2000). Anabolic-androgenic steroids. In Performance-Enhancing Substances in Sport and Exercise (pp. 1-24). Human Kinetics.
